Biosenic SA

BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles

27 May 2024 11:00:00 By Nasdaq GlobeNewswire

BioSenic provides First Quarter 2024 Business Update

24 May 2024 10:59:59 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

30 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles

26 Apr 2024 11:30:00 By Nasdaq GlobeNewswire

BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023

24 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Transparency notifications received from François Rieger

18 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic provides further information on its restructuring plan

12 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles

11 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

29 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress

20 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease

12 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

29 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic raises €500,000 in private placement of new shares with established new investors

02 Feb 2024 11:30:00 By Nasdaq GlobeNewswire

BioSenic provides support to forthcoming European conference on graft-versus-host disease  

31 Jan 2024 04:30:00 By Nasdaq GlobeNewswire

BioSenic patent granted in Canada for broader protection of ATO therapeutic platform

30 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress

25 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis

23 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment

15 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Transparency notifications received from François Rieger

15 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer

10 Jan 2024 01:00:00 By Nasdaq GlobeNewswire